Get involved

Claim

Opening the claim…

No cancer outcome differs significantly between GLP-1 receptor agonists and placebo after correction in these trials: reports of any malignant neoplasm (1.03, 95% CI 0.97 to 1.09, q = 0.48), of the cancers linked to excess body fat (1.09, 0.99 to 1.19, q = 0.20) and of pancreatic cancer (0.99, 0.75 to 1.32, q = 0.95). Thyroid cancer reports are nominally higher (67 against 32; 1.61, 1.02 to 2.55, p = 0.042; Peto's odds ratio 1.61, 1.07 to 2.41) but not after correction (q = 0.14), so the trials neither confirm nor exclude an increase. · sciencejournal.ai